Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program
Inflammatory Bowel Diseases · 01.09.2025 · 31 (9) · 2352-2362
DOI: 10.1093/ibd/izae308 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 04.04.2025. Verfasst von Gary R Lichtenstein und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Background
Patient age can impact the safety and efficacy of ulcerative colitis (UC) treatments. Etrasimod is an oral, once daily (QD), selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active UC. Here, we evaluate the impact of age on etrasimod safety and efficacy in patients with UC in the phase 3 ELEVATE UC clinical program.
Methods
Data were pooled from ELEVATE UC 52 and ELEVATE UC 12 in patients receiving etrasimod 2 mg QD or placebo. Proportions and incidence rates (IRs) per 100 patient-years of treatment-emergent adverse events (AEs) were stratified by age (<40, 40-59, and ≥60 years). With the same age stratifications, efficacy was evaluated in patients with baseline Modified Mayo scores of 5-9 and 4-9 for the primary efficacy endpoint (clinical remission) and secondary efficacy endpoints.
Results
Overall, 787 patients were enrolled (<40 years, n = 420 [53.4%]; 40-59 years, n = 276 [35.1%]; and ≥60 years, n = 91 [11.6%]). Arthralgia, fatigue, and hypertension IRs were higher in older patients, irrespective of treatment. Serious AEs and AEs leading to treatment discontinuation were low and consistent across age groups. Significantly more patients receiving etrasimod 2 mg QD vs placebo achieved efficacy endpoints, regardless of age.
Conclusions
The safety profile of etrasimod 2 mg QD in the ELEVATE UC population was consistent across age groups, with no change in the incidence of AEs. Patients receiving etrasimod vs placebo showed significant clinical benefit, regardless of age. ClinicalTrials.gov NCT03945188; NCT03996369.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA, USA.
- Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
- IBD Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK.
- Department of Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India.
- Division of Gastroenterology and Hepatology, Johns Hopkins School of Medicine, Washington, DC, USA.
ORCID-Profile: Gary R Lichtenstein, Jessica R Allegretti, Silvio Danese
Förderung
- Pfizer
Zitieren
APA
Lichtenstein, G. R., Allegretti, J. R., Loftus, E. V., Irving, P. M., Banerjee, R., Charabaty, A., Kuehbacher, T., Bananis, E., Woolcott, J. C., Dalam, A. B., Lazin, K., Keating, M., McDonnell, A., & Danese, S. (2025). Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program. Inflammatory Bowel Diseases, 31(9), 2352-2362. https://doi.org/10.1093/ibd/izae308
Vancouver
Lichtenstein GR, Allegretti JR, Loftus EV, Irving PM, Banerjee R, Charabaty A, et al. Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program. Inflammatory Bowel Diseases. 2025;31(9):2352-2362. doi:10.1093/ibd/izae308
BibTeX
@article{Lichtenstein2025,
author = {Lichtenstein, Gary R and Allegretti, Jessica R and Loftus, Edward V and Irving, Peter M and Banerjee, Rupa and Charabaty, Aline and Kuehbacher, Tanja and Bananis, Eustratios and Woolcott, John C and Dalam, Alexis B and Lazin, Krisztina and Keating, Michael and McDonnell, Aoibhinn and Danese, Silvio},
title = {Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program},
journal = {Inflammatory Bowel Diseases},
year = {2025},
volume = {31},
number = {9},
pages = {2352--2362},
doi = {10.1093/ibd/izae308}
}
EUVIMED